الفهرس 
General Introduction
Nanoparticles as a drug delivery systemOnly 14 pages are availabe for public view
 |  | from | 98 |  |  |
| | | from | 98 | | |
Abstract
Chrysin is a flavonoid with various biological and therapeutic properties.
However, its poor oral bioavailability and solubility are challenging barriers against its
therapeutic use, which can be circumvented via encapsulation in a suitable nanocarrier.
Therefore, the aim of this work was to prepare polymeric chrysin nanocapsules based on
polylactic-glycolic acid (PLGA) with improved oral therapeutic potential, by
optimization of their physicochemical properties using response surface methodology.
Diabetes was induced in an animal model using streptozotocin to assess the antihyperglycemic activity of the selected formulation, and hyperlipidemia was induced in
another animal model using a high fat diet to assess its anti-hyperlipidemic activity.
Results revealed that the selected chrysin nanocapsular formulation exhibited particle
size of 176±2.10 nm, polydispersity index of 0.22±0.01, negative zeta potential of -6.23
± 0.178 to -0.04 ± 0.17, drug entrapment efficiency of 87.10%±6.71, a controlled release
of chrysin over a period of 24 h, and a significant physical stability after storage at 4ºC
for 3 months. Compared to chrysin suspension, the selected nanocapsular formulation
exhibited marked anti-hyperglycemic effect for up to 24 h, as well as superior antihyperlipidemic potential for 28 days. These improvements in chrysin therapeutic action
after its encapsulation into polymeric nanocapsules delineate it as a promising remedy
for oral treatment of diabetes and hyperlipidemia.
Keywords: chrysin, Nanocapsules, Controlled drug delivery, Hyperlipidemia,
Diabetes, Pharmacodynamic study, PLGA.